GWN Securities Inc. Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

GWN Securities Inc. acquired a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 13,127 shares of the biopharmaceutical company's stock, valued at approximately $395,000.

Other hedge funds have also recently made changes to their positions in the company. Victory Capital Management Inc. raised its stake in TG Therapeutics by 24.7% in the third quarter. Victory Capital Management Inc. now owns 32,679 shares of the biopharmaceutical company's stock worth $764,000 after buying an additional 6,467 shares in the last quarter. Oppenheimer & Co. Inc. bought a new position in shares of TG Therapeutics in the 3rd quarter worth approximately $759,000. KBC Group NV raised its position in shares of TG Therapeutics by 30.5% in the 3rd quarter. KBC Group NV now owns 4,675 shares of the biopharmaceutical company's stock worth $109,000 after acquiring an additional 1,092 shares in the last quarter. Empowered Funds LLC lifted its stake in shares of TG Therapeutics by 3.1% in the 3rd quarter. Empowered Funds LLC now owns 46,431 shares of the biopharmaceutical company's stock valued at $1,086,000 after purchasing an additional 1,386 shares during the period. Finally, Mutual of America Capital Management LLC bought a new stake in shares of TG Therapeutics during the third quarter valued at approximately $469,000. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Stock Down 1.4 %

TGTX stock traded down $0.58 during trading on Thursday, hitting $41.89. 2,205,020 shares of the stock traded hands, compared to its average volume of 2,973,437. The stock has a market cap of $6.58 billion, a price-to-earnings ratio of -418.86 and a beta of 2.30. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. TG Therapeutics, Inc. has a 1 year low of $12.93 and a 1 year high of $43.17. The firm's 50 day moving average is $32.63 and its two-hundred day moving average is $29.41.

Remove Ads

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.08 by $0.07. The firm had revenue of $108.19 million for the quarter, compared to analysts' expectations of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. On average, sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Analyst Upgrades and Downgrades

TGTX has been the subject of several recent research reports. StockNews.com raised TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. JPMorgan Chase & Co. lifted their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an "overweight" rating in a research report on Monday, November 25th. Finally, HC Wainwright restated a "buy" rating and issued a $55.00 price objective on shares of TG Therapeutics in a report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $40.67.

Insiders Place Their Bets

In related news, CFO Sean A. Power sold 10,021 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the sale, the chief financial officer now directly owns 660,611 shares of the company's stock, valued at $18,847,231.83. This trade represents a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 10.50% of the company's stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.